4/A: BiomX Inc. Director Alan Charles Moses Corrects Error in Form 4 Filing

Alan Charles Moses, a director at BiomX Inc., filed an amended Form 4 to correct a reporting error regarding the acquisition of derivative securities.

Summary

• Alan Charles Moses, a director of BiomX Inc., filed an amendment to a previously submitted Form 4.
• The amendment corrects an error in Table II, Column 5, where the number of derivative securities acquired was incorrectly reported as disposed of instead of acquired.
• The transaction involves options to buy 17,600 shares of BiomX Inc. common stock at an exercise price of $0.538.
• These options vest over four years, starting with 25% vesting on April 14, 2026, and the remainder vesting in 12 equal quarterly installments over three years.
• No other changes were made to the originally filed Form 4.

Sentiment

Score: 7

Explanation: The document is a routine regulatory filing correcting a clerical error. It doesn't contain information that would significantly impact investor sentiment, but the correction itself is a positive sign of diligence.

Industry Context

Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders, ensuring transparency and compliance with SEC regulations.

Stakeholder Impact

• The correction of the filing ensures accurate information is available to shareholders.

Key Dates

Keywords

Form 4, amendment, derivative securities, options, BiomX Inc., Alan Charles Moses, beneficial ownership, director